Nevro’s patent describes a method for pain treatment through electrical stimulation. The approach involves delivering an electrical therapy signal, ranging from 2 Hz to 100 kHz, to a patient’s spinal cord, targeting glial cell activity to alleviate pain. GlobalData’s report on Nevro gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nevro, Neuromodulation implants was a key innovation area identified from patents. Nevro's grant share as of June 2024 was 60%. Grant share is based on the ratio of number of grants to total number of patents.
Electrical stimulation method for treating pain via glial cells
The granted patent US11998744B1 outlines a method for treating pain in patients by altering the activity of glial cells through the application of electrical therapy signals. The method involves programming a signal generator to deliver these signals to specific neural populations in the spinal cord, particularly at the thoracic vertebral level. The electrical therapy signals operate within a frequency range of 2 Hz to 100 kHz and can be adjusted for pulse width (10 to 333 microseconds) and amplitude (0.1 to 20 mA). Notably, the therapy aims to produce changes in glial cell activity, which may include downregulation, modulation of interactions with neuronal cells, or even an increase in glial activity, all contributing to the reduction of chronic pain.
Further claims detail the specific biochemical changes that may occur as a result of the therapy, such as decreased release of proinflammatory cytokines, nitric oxide, excitatory amino acids, or prostaglandins from glial cells. The patent also emphasizes that the electrical therapy signals can be programmed to avoid causing paresthesia in patients, ensuring comfort during treatment. Overall, the methods described in this patent provide a novel approach to pain management by targeting glial cell activity and expression, potentially offering new avenues for chronic pain relief.
To know more about GlobalData’s detailed insights on Nevro, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
